DrugPatentWatch Database Preview
Heron Theraps Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for HERON THERAPS INC, and what generic alternatives to HERON THERAPS INC drugs are available?
HERON THERAPS INC has two approved drugs.
There are fourteen US patents protecting HERON THERAPS INC drugs.
There are twenty-four patent family members on HERON THERAPS INC drugs in ten countries and seven supplementary protection certificates in four countries.
Summary for Heron Theraps Inc
| International Patents: | 24 |
| US Patents: | 14 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Heron Theraps Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | RX | Yes | Yes | 8,252,304 | Start Trial | Y | Start Trial | |||
| Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | 9,561,229 | Start Trial | Y | Start Trial | |||
| Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | RX | Yes | Yes | 6,790,458 | Start Trial | Y | Start Trial | |||
| Heron Theraps Inc | SUSTOL | granisetron | INJECTION, EXTENDED RELEASE;SUBCUTANEOUS | 022445-001 | Aug 9, 2016 | RX | Yes | Yes | 9,913,910 | Start Trial | Start Trial | ||||
| Heron Theraps Inc | CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296-001 | Nov 9, 2017 | RX | Yes | Yes | 10,624,850 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Heron Theraps Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3193830 | Start Trial |
| Taiwan | I407966 | Start Trial |
| Japan | 2017008113 | Start Trial |
| China | 101052376 | Start Trial |
| Japan | 2017008113 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Heron Theraps Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0734381 | PA2004002,C0734381 | Lithuania | Start Trial | PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111 |
| 0734381 | SPC/GB04/011 | United Kingdom | Start Trial | PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113 |
| 0748320 | SPC/GB08/021 | United Kingdom | Start Trial | PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111 |
| 0734381 | 04C0010 | France | Start Trial | PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111 |
| 0748320 | 08C0019 | France | Start Trial | PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
